NORTH-REG Dwell-Time Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

314 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-03

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Previous studies show that the majority NMIBC patients experience side effects to BCG and therefore terminate the instillations before completing all planned instillations. This will increase their risk of recurrence and potential cystectomy. The purpose of this study is to investigate if NMIBC patients who experience severe side effects to BCG instillations will experience fewer or less severe side effects if reducing dwell-time of BCG instillations.

The study will include patients from Denmark, Iceland, Norway and Sweden.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.

NCT01694108

Prospective Single-blind Clinical +2 more

COMPLETED PHASE4

Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents

NCT02378207

Tuberculosis

COMPLETED PHASE1

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes

NCT05180591

Diabetes Mellitus, Type 1 Diabetes type1 Autoimmune Diabetes

RECRUITING PHASE2

BCG Revaccination Study in Diabetic and Non-Diabetic Adults

NCT06246851

Tuberculosis

ENROLLING_BY_INVITATION NA

Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?

NCT04658680

Infant Mortality BCG

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 8,000 patients are diagnosed with bladder cancer (BC) in the Nordic countries every year. The majority of BC patients are diagnosed with non-muscle invasive bladder cancer (NMIBC). The majority of NMIBC are treated with Bacillus Calmette-Guérin vaccine (BCG) as adjuvant treatment but for carcinoma in situ it is the primary treatment. BCG is known to give a lot of side effects both local and systemic, the severity of these can lead to premature termination of the treatment.

The object of this PhD project is to investigate if reduced dwell time, the time the BCG is in the bladder, will decrease the severity of side effects due to BCG instillations.

This will be investigated in a Nordic setting and the project will be done as a two-armed randomized clinical trial.

By decreasing the severity of side effects, we hypothesize the number of patients completing all planned instillations will increase and thereby decrease the risk of the BC evolving into a more aggressive type.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Side Effect of Drug

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

multi-center, multi-national, two-armed, randomized, open-label, investigator-initiated clinical controlled - phase IV trial.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Study Subjects randomized to the interventional arm will be assigned to BCG induction therapy once-weekly for 6 weeks and subsequent 1 year of maintenance (6+3x3) of which dwell-time during the first of the 6 induction instillations is 2 hours.

If side effects are registered before the second and all further instillations, Study Subject in the intervention arm will be reduced in dwell-time according to the grading of side effects as given by the study algorithm.

Group Type EXPERIMENTAL

Bacillus Calmette Guerin

Intervention Type DRUG

The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.

Control

The Study Subjects will be treated according to guidelines with BCG instillation therapy once weekly for 6 weeks and subsequent 1 year of maintenance therapy (6+3x3) with 2 hours of dwelltime.

Group Type ACTIVE_COMPARATOR

Bacillus Calmette Guerin

Intervention Type DRUG

The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bacillus Calmette Guerin

The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years of age at the time of signing the Informed Consent Form
* Signed Informed Consent Form
* Patients with NMIBC where BCG therapy including maintenance for 1 year is planned for one of the following histopathological findings:
* Ta high grade without CIS
* CIS with or without previous or concomitant Ta tumors
* T1 with or without CIS
* Is, according to the Investigator's judgement, able to comply with the trial protocol
* Ability to understand the Patient Information Sheet orally and in writing

Exclusion Criteria

* Previous BCG instillations within the last 2 years, because of the risk of not having cleared potential previos side effects.
* T1 tumors where re-resection had not been performed
* TUR-B, bladder biopsy or traumatic catheterization within 2 weeks.
* Previous or current MIBC
* Progression defined as progrssion to T1-tumour, T2+\_tumour or cystectomy irrespectievely of indication or development of metastatic urothelial cancer irrespectively of tumour stage
* Contraindications to BCG
* Incontinence
* Bilateral nephrostomy catheters; unilateral nephrostomy catheter is allowed if permanent for the duration of all inistallations with BCG and a normally functioning kidney.
* Need for catheter a demeure at the time of instillation
* Immune Suppressing medication (cancer therapy e.g cytostatic medicinal products, radiation, local and systemic steroids like e.g. prednisolone is permitted)
* Reduced immune response (leukaemia, lymphoma)
* Known allergy or sensitivity to BCG
* HIV infection
* Signs of active tuberculosis
* Any type of previosly radiation therapy involving the bladder.
* Concomitant invasive cancer within 5 years other than non-melanoma skin cancer and protate cancer without metastasis
* Current urinary tract infection
* Patient with visible hematuria
* Current alcohol and/or drug abuse
* Has a mental or legal incapacitation or another condition which impair the subject's ability to participate
* Has participated in another interventional clinical study and treatment with another investigational product 30 days prior to randomization
* For women study subjects: Pregnancy or breastfeeding
* For women Study subjects of childbearing potential: unless they are using highly effective methods of contraception from the first BCG instillations until 14 days after last dose of BCG treatment, which are defined as total abstinence, female sterilization, use of oral methods of contraception or placement of an intrauterine contraception devices.
* For male Study Subjects: unless they are using highly effective methods of contraception from the first BCG instillation until for 14 days after last dose of BCG treatment, which is defined as total abstinence or use of condoms.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes